Ann Surg 2021 Mar 3. Epub 2021 Mar 3.
*Department of Investigative Pathology, Tohoku University Graduate School of Medicine, Sendai, 980-8575, Japan †Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, 065-0033, Japan ‡Cancer Genomics and Precision Medicine, Department of Medicine, Asahikawa Medical University, Asahikawa, 078-8510, Japan §Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, 980-8575, Japan ¶Department of Surgery I, Yamagata University Graduate School of Medical Science, Yamagata, 990-9585, Japan. ||Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
Objective: We aimed to elucidate the clinicopathobiological significance of Serine/Threonine Kinase 11 (STK11) in pancreatic intraductal papillary mucinous neoplasms (IPMNs).
Background: STK11 is a tumor suppressor involved in certain IPMNs, however, its significance is not well known.
Methods: In 184 IPMNs without Peutz-Jeghers syndrome, we analyzed expression of STK11 and phosphorylated-AMPKα in all cases, and p16, p53, SMAD4, and β-catenin in 140 cases by immunohistochemistry; and we analyzed mutations in 37 genes, including whole coding exons of STK11, CDKN2A, TP53, and SMAD4, and hotspots of KRAS, BRAF, and GNAS in 64 cases by targeted sequencing. Read More